These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 27216181)

  • 21. Galectin-3 immunodetection may improve cytological diagnosis of occult papillary thyroid carcinoma.
    Pisani T; Vecchione A; Giovagnolii MR
    Anticancer Res; 2004; 24(2C):1111-2. PubMed ID: 15154632
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Atypical thyroid nodules express both HBME-1 and Galectin-3, two phenotypic markers of papillary thyroid carcinoma.
    Coli A; Bigotti G; Parente P; Federico F; Castri F; Massi G
    J Exp Clin Cancer Res; 2007 Jun; 26(2):221-7. PubMed ID: 17725102
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Follicular thyroid neoplasms can be classified as low- and high-risk according to HBME-1 and Galectin-3 expression on liquid-based fine-needle cytology.
    Fadda G; Rossi ED; Raffaelli M; Pontecorvi A; Sioletic S; Morassi F; Lombardi CP; Zannoni GF; Rindi G
    Eur J Endocrinol; 2011 Sep; 165(3):447-53. PubMed ID: 21724837
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Simultaneous immunohistochemical expression of HBME-1 and galectin-3 differentiates papillary carcinomas from hyperfunctioning lesions of the thyroid.
    Rossi ED; Raffaelli M; Mule' A; Miraglia A; Lombardi CP; Vecchio FM; Fadda G
    Histopathology; 2006 Jun; 48(7):795-800. PubMed ID: 16722927
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Development and characterization of clinical-grade 89Zr-trastuzumab for HER2/neu immunoPET imaging.
    Dijkers EC; Kosterink JG; Rademaker AP; Perk LR; van Dongen GA; Bart J; de Jong JR; de Vries EG; Lub-de Hooge MN
    J Nucl Med; 2009 Jun; 50(6):974-81. PubMed ID: 19443585
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Galectin-3 and laminin expression in neoplastic and non-neoplastic thyroid tissue.
    Fernández PL; Merino MJ; Gómez M; Campo E; Medina T; Castronovo V; Sanjuán X; Cardesa A; Liu FT; Sobel ME
    J Pathol; 1997 Jan; 181(1):80-6. PubMed ID: 9072007
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Thyroid peroxidase and galectin-3 immunostaining in differentiated thyroid carcinoma with clinicopathologic correlation.
    Savin S; Cvejic D; Isic T; Paunovic I; Tatic S; Havelka M
    Hum Pathol; 2008 Nov; 39(11):1656-63. PubMed ID: 18657294
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Site-specifically 89Zr-labeled monoclonal antibodies for ImmunoPET.
    Tinianow JN; Gill HS; Ogasawara A; Flores JE; Vanderbilt AN; Luis E; Vandlen R; Darwish M; Junutula JR; Williams SP; Marik J
    Nucl Med Biol; 2010 Apr; 37(3):289-97. PubMed ID: 20346868
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Low galectin-3 capacity to discriminate thyroid lesions].
    De-León-Mazariegos R; Canedo-Patzi M; Pérez-Enríquez B; Candanedo-Gonzalez F; Saqui-Salces M; Gamboa-Domínguez A; Rull-Rodrigo JA
    Rev Invest Clin; 2004; 56(5):623-8. PubMed ID: 15776867
    [TBL] [Abstract][Full Text] [Related]  

  • 30. 18F-FDG PET reduces unnecessary hemithyroidectomies for thyroid nodules with inconclusive cytologic results.
    de Geus-Oei LF; Pieters GF; Bonenkamp JJ; Mudde AH; Bleeker-Rovers CP; Corstens FH; Oyen WJ
    J Nucl Med; 2006 May; 47(5):770-5. PubMed ID: 16644746
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Diagnostic value of galectin-3, HBME-1, cytokeratin 19, high molecular weight cytokeratin, cyclin D1 and p27(kip1) in the differential diagnosis of thyroid nodules.
    Park YJ; Kwak SH; Kim DC; Kim H; Choe G; Park DJ; Jang HC; Park SH; Cho BY; Park SY
    J Korean Med Sci; 2007 Aug; 22(4):621-8. PubMed ID: 17728499
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Expression of cytokeratin 19, HBME-1 and galectin-3 in neoplastic and nonneoplastic thyroid lesions.
    Mataraci EA; Ozgüven BY; Kabukçuoglu F
    Pol J Pathol; 2012 Mar; 63(1):58-64. PubMed ID: 22535608
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Galectin-3 messenger ribonucleic acid and protein are expressed in benign thyroid tumors.
    Martins L; Matsuo SE; Ebina KN; Kulcsar MA; Friguglietti CU; Kimura ET
    J Clin Endocrinol Metab; 2002 Oct; 87(10):4806-10. PubMed ID: 12364477
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Diagnosis of incidental thyroid nodules on 18F-fluorodeoxyglucose positron emission tomography imaging: are these significant?
    Sharma SD; Jacques T; Smith S; Watters G
    J Laryngol Otol; 2015 Jan; 129(1):53-6. PubMed ID: 25496842
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [The expression of galectin-3 in nodular thyroid goitre].
    Chen WJ; Yu MH; Xu Y; Shen J
    Zhonghua Nei Ke Za Zhi; 2006 Jun; 45(6):452-5. PubMed ID: 16831319
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Galectin-3 and oncofetal-fibronectin expression in thyroid neoplasia as assessed by reverse transcription-polymerase chain reaction and immunochemistry in cytologic and pathologic specimens.
    Giannini R; Faviana P; Cavinato T; Elisei R; Pacini F; Berti P; Fontanini G; Ugolini C; Camacci T; De Ieso K; Miccoli P; Pinchera A; Basolo F
    Thyroid; 2003 Aug; 13(8):765-70. PubMed ID: 14558920
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The use of a combination of galectin-3 and thyroid peroxidase for the diagnosis and prognosis of thyroid cancer.
    Weber KB; Shroyer KR; Heinz DE; Nawaz S; Said MS; Haugen BR
    Am J Clin Pathol; 2004 Oct; 122(4):524-31. PubMed ID: 15487449
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Targeting MT1-MMP as an ImmunoPET-Based Strategy for Imaging Gliomas.
    de Lucas AG; Schuhmacher AJ; Oteo M; Romero E; Cámara JA; de Martino A; Arroyo AG; Morcillo MÁ; Squatrito M; Martinez-Torrecuadrada JL; Mulero F
    PLoS One; 2016; 11(7):e0158634. PubMed ID: 27462980
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immunohistochemical localization of galectin-3 in malignant and benign human thyroid tissue.
    Cvejic D; Savin S; Paunovic I; Tatic S; Havelka M; Sinadinovic J
    Anticancer Res; 1998; 18(4A):2637-41. PubMed ID: 9703921
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Role of 18F-fluorodeoxyglucose positron emission tomography in preoperative assessment of cytologically indeterminate thyroid nodules.
    Sebastianes FM; Cerci JJ; Zanoni PH; Soares J; Chibana LK; Tomimori EK; de Camargo RY; Izaki M; Giorgi MC; Eluf-Neto J; Meneghetti JC; Pereira MA
    J Clin Endocrinol Metab; 2007 Nov; 92(11):4485-8. PubMed ID: 17684046
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.